Ayer Amit, Page Brandi R, Lucas John T, Bourland J Daniel, Oliver Eric R, Tatter Stephen B, Ellis Thomas L, Chan Michael D
Department of Neurosurgery, Northwestern University, Chicago, Illinois, USA.
Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
J Radiosurg SBRT. 2014;3(2):131-137.
Cavernous sinus metastases represent difficult clinical scenarios because of the lack of surgical options. We investigate the use of Gamma Knife stereotactic radiosurgery (GKRS) as a treatment option of these metastases.
To determine the patterns of failure for cavernous sinus metastases and to identify factors that predict for improved outcomes.
This is a retrospective review of 19 patients treated with GKRS for cavernous sinus metastases over a 9-year period between May 2002 and October 2011. The median marginal tumor dose was 18 Gy. Patients were followed with serial imaging. Kaplan Meier analysis was used to estimate local control and overall survival. Fischer exact test was used to determine any predictive factors for local control or survival.
Median follow-up time was 22.4 months. Kaplan Meier estimate of overall survival at 1, 2, and 4 years was 76%, 44%, and 44% survival, respectively. 11 patients experienced intracranial failure. Of these, 7 (64%) were local and 4 (36%) were distant intracranial failures. Local control was 76%, 44%, and 44% at 1, 2 and 4 years, respectively. Six of seven local failures in the series were considered to be marginal failures because they were abutting the 50% isodose volume. Head and neck primary tumors were associated with 86% of local failures (P = 0.017) and was the only factor that predicted for local failure.
GKRS appears to be a feasible and safe modality for treatment of cavernous sinus metastases. Local failures appear to be due to a marginal miss of microscopically occult disease.
由于缺乏手术选择,海绵窦转移瘤代表着困难的临床情况。我们研究使用伽玛刀立体定向放射外科治疗(GKRS)作为这些转移瘤的一种治疗选择。
确定海绵窦转移瘤的失败模式,并识别预测改善结局的因素。
这是一项对19例在2002年5月至2011年10月的9年期间接受GKRS治疗海绵窦转移瘤患者的回顾性研究。中位边缘肿瘤剂量为18 Gy。对患者进行系列影像学随访。采用Kaplan-Meier分析来估计局部控制率和总生存率。使用Fisher精确检验来确定局部控制或生存的任何预测因素。
中位随访时间为22.4个月。Kaplan-Meier估计1年、2年和4年的总生存率分别为76%、44%和44%。11例患者出现颅内失败。其中,7例(64%)为局部失败,4例(36%)为远处颅内失败。1年、2年和4年的局部控制率分别为76%、44%和44%。该系列中7例局部失败中有6例被认为是边缘性失败,因为它们紧邻50%等剂量体积。头颈部原发性肿瘤与86%的局部失败相关(P = 0.017),并且是预测局部失败的唯一因素。
GKRS似乎是治疗海绵窦转移瘤的一种可行且安全的方式。局部失败似乎是由于显微镜下隐匿性疾病的边缘遗漏。